Savara Pharmaceuticals is an Austin-based emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. Savara’s lead product candidate is AeroVanc™, the first inhaled antibiotic being developed to address the growing population of MRSA-infected cystic fibrosis patients.

If you wish to stay informed of our progress, please:

Follow us on Twitter
Follow us on LinkedIn
Follow us on Facebook
 

or Contact Us.